• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

未行冰冻切片的肺段切除术患者中意外的淋巴结分期上调:一项多中心回顾性队列研究。

Unforeseen nodal upstaging in patients undergoing segmentectomy without frozen section: a multicenter retrospective cohort study.

作者信息

Huang Lin, Brunelli Alessandro, Stefanou Demetrios, Zanfrini Edoardo, Donlagic Abid, Gonzalez Michel, Petersen René Horsleben

机构信息

Department of Cardiothoracic Surgery, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen Ø, Denmark.

Department of Thoracic Surgery, St. James's University Hospital, Leeds, UK.

出版信息

Surg Endosc. 2025 Apr;39(4):2296-2303. doi: 10.1007/s00464-025-11612-9. Epub 2025 Feb 13.

DOI:10.1007/s00464-025-11612-9
PMID:39948264
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11933133/
Abstract

OBJECTIVE

The study aimed to evaluate the risk of unforeseen nodal upstaging (pN+) after pulmonary segmentectomy without intraoperative frozen section.

METHODS

We conducted a retrospective analysis for consecutive patients who underwent segmentectomy for clinical stage IA1-2 non-small cell lung cancer (cIA1-2 NSCLC) in three centers between January 2017 and December 2022. A backward stepwise logistic regression analysis for variables with P < 0.1 in univariable analysis was performed to predict pN+. Kaplan-Meier analysis with log-rank test evaluated the discrepancy for overall (OS) and recurrence-free survivals (RFS).

RESULTS

Among 478 patients included in the final analysis, 19 (4.0%) had pN+, including 10 (2.1%) pN1, 6 (1.3%) pN2, and 3 (0.6%) pN1+2. With a median follow-up of 23.5 months (interquartile range 12.6-39.0), patients with pN+ had poorer OS compared to those with pN0 (3-year OS: 70.2% vs. 89.7%, P = 0.002). However, there was no significant difference in RFS and recurrence. The maximum standardized uptake value (SUVmax) of tumor in positron emission tomography scan ≥ 4.5 (versus < 4.5) was the only independent factor for pN + (odds ratio 3.5). Patients with a SUVmax ≥ 4.5 had 7.3% pN+, which was associated with poorer OS and similar RFS and recurrence compared to pN0. In contrast, those with a SUVmax < 4.5 had 2.2% pN+, which had comparable recurrence and survival to pN0.

CONCLUSION

Unforeseen nodal upstaging in segmentectomy for cIA1-2 NSCLC is low. Frozen section of lymph nodes may be necessary for lesions with high metabolic activity.

摘要

目的

本研究旨在评估在未进行术中冰冻切片的情况下,肺段切除术后意外出现淋巴结分期上调(pN+)的风险。

方法

我们对2017年1月至2022年12月期间在三个中心接受临床IA1-2期非小细胞肺癌(cIA1-2 NSCLC)肺段切除术的连续患者进行了回顾性分析。对单因素分析中P<0.1的变量进行向后逐步逻辑回归分析以预测pN+。采用Kaplan-Meier分析和对数秩检验评估总生存期(OS)和无复发生存期(RFS)的差异。

结果

在最终分析纳入的478例患者中,19例(4.0%)出现pN+,其中10例(2.1%)为pN1,6例(1.3%)为pN2,3例(0.6%)为pN1+2。中位随访时间为23.5个月(四分位间距12.6 - 39.0),pN+患者的OS较pN0患者差(3年OS:70.2%对89.7%,P = 0.002)。然而,RFS和复发方面无显著差异。正电子发射断层扫描中肿瘤的最大标准化摄取值(SUVmax)≥4.5(对比<4.5)是pN+的唯一独立因素(比值比3.5)。SUVmax≥4.5的患者pN+发生率为7.3%,与pN0相比,其OS较差,RFS和复发情况相似。相比之下SUVmax<4.5的患者pN+发生率为2.2%,其复发和生存情况与pN0相当。

结论

cIA1-2 NSCLC肺段切除术中意外出现淋巴结分期上调的情况较少。对于具有高代谢活性的病变,可能需要进行淋巴结冰冻切片检查。

相似文献

1
Unforeseen nodal upstaging in patients undergoing segmentectomy without frozen section: a multicenter retrospective cohort study.未行冰冻切片的肺段切除术患者中意外的淋巴结分期上调:一项多中心回顾性队列研究。
Surg Endosc. 2025 Apr;39(4):2296-2303. doi: 10.1007/s00464-025-11612-9. Epub 2025 Feb 13.
2
Association of Pathologic Nodal Staging Quality With Survival Among Patients With Non-Small Cell Lung Cancer After Resection With Curative Intent.具有治愈意图的非小细胞肺癌切除术后病理淋巴结分期质量与生存的相关性研究。
JAMA Oncol. 2018 Jan 1;4(1):80-87. doi: 10.1001/jamaoncol.2017.2993.
3
Oncologic outcomes of segmentectomy compared with lobectomy for clinical stage IA lung adenocarcinoma: propensity score-matched analysis in a multicenter study.对比解剖性肺段切除术与肺叶切除术治疗临床ⅠA 期肺腺癌的肿瘤学结果:多中心研究中的倾向性评分匹配分析。
J Thorac Cardiovasc Surg. 2013 Aug;146(2):358-64. doi: 10.1016/j.jtcvs.2013.02.008. Epub 2013 Mar 8.
4
Clinical Predictors of Nodal Metastases in Peripherally Clinical T1a N0 Non-Small Cell Lung Cancer.外周临床T1a N0期非小细胞肺癌淋巴结转移的临床预测因素
Ann Thorac Surg. 2017 Oct;104(4):1153-1158. doi: 10.1016/j.athoracsur.2017.02.074. Epub 2017 May 24.
5
The Relationship Between Nodal Metastases and Primary Location in Stage I Non-Small Cell Lung Cancer.Ⅰ期非小细胞肺癌的淋巴结转移与原发部位的关系。
J Surg Res. 2024 Oct;302:578-584. doi: 10.1016/j.jss.2024.07.102. Epub 2024 Aug 23.
6
Tumour spread through air spaces is a determiner for treatment of clinical stage I non-small cell lung Cancer: Thoracoscopic segmentectomy vs lobectomy.肿瘤通过气腔播散是临床I期非小细胞肺癌治疗的一个决定因素:胸腔镜肺段切除术与肺叶切除术的比较
Lung Cancer. 2025 Mar;201:108438. doi: 10.1016/j.lungcan.2025.108438. Epub 2025 Feb 7.
7
Is segmentectomy potentially adequate for clinical stage IA3 non-small cell lung cancer.肺段切除术对临床IA3期非小细胞肺癌是否可能足够?
Interdiscip Cardiovasc Thorac Surg. 2025 Mar 5;40(3). doi: 10.1093/icvts/ivaf064.
8
Impact of number of dissected lymph nodes on recurrence and survival following thoracoscopic segmentectomy for clinical stage I non-small cell lung cancer.解剖淋巴结数量对临床 I 期非小细胞肺癌胸腔镜肺段切除术后复发和生存的影响。
Lung Cancer. 2024 Jul;193:107846. doi: 10.1016/j.lungcan.2024.107846. Epub 2024 Jun 2.
9
The prevalence of nodal upstaging during robotic lung resection in early stage non-small cell lung cancer.机器人肺切除术中早期非小细胞肺癌淋巴结分期升级的发生率。
Ann Thorac Surg. 2014 Jun;97(6):1901-6; discussion 1906-7. doi: 10.1016/j.athoracsur.2014.01.064. Epub 2014 Apr 14.
10
A national study of nodal upstaging after thoracoscopic versus open lobectomy for clinical stage I lung cancer.一项全国性研究显示,在临床 I 期肺癌中,与开胸肺叶切除术相比,电视辅助胸腔镜手术(VATS)肺叶切除术会导致淋巴结分期升高。
Ann Thorac Surg. 2013 Sep;96(3):943-9; discussion 949-50. doi: 10.1016/j.athoracsur.2013.04.011. Epub 2013 May 16.

本文引用的文献

1
Outcomes of Patients Undergoing Segmentectomy for Occult Node-Positive Clinical Stage IA Lung Cancer.隐匿性淋巴结阳性临床ⅠA 期肺癌患者行解剖性肺段切除术的结果。
Ann Thorac Surg. 2024 Sep;118(3):655-663. doi: 10.1016/j.athoracsur.2024.05.031. Epub 2024 Jun 10.
2
Alectinib in Resected -Positive Non-Small-Cell Lung Cancer.阿来替尼治疗可切除阳性非小细胞肺癌。
N Engl J Med. 2024 Apr 11;390(14):1265-1276. doi: 10.1056/NEJMoa2310532.
3
Lobectomy, segmentectomy, or wedge resection for peripheral clinical T1aN0 non-small cell lung cancer: A post hoc analysis of CALGB 140503 (Alliance).
外周临床T1aN0非小细胞肺癌的肺叶切除术、肺段切除术或楔形切除术:CALGB 140503(联盟)的事后分析
J Thorac Cardiovasc Surg. 2024 Jan;167(1):338-347.e1. doi: 10.1016/j.jtcvs.2023.07.008. Epub 2023 Jul 18.
4
Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial.阿特珠单抗辅助化疗用于可切除 II-IIIA 期非小细胞肺癌的总生存期:一项随机、多中心、开放标签、III 期试验(IMpower010)。
Ann Oncol. 2023 Oct;34(10):907-919. doi: 10.1016/j.annonc.2023.07.001. Epub 2023 Jul 17.
5
Overall Survival with Osimertinib in Resected -Mutated NSCLC.奥希替尼治疗可切除突变型 NSCLC 的总生存期。
N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4.
6
European Society of Thoracic Surgeons expert consensus recommendations on technical standards of segmentectomy for primary lung cancer.欧洲胸外科医师协会关于原发性肺癌肺段切除术技术标准的专家共识建议
Eur J Cardiothorac Surg. 2023 Jun 1;63(6). doi: 10.1093/ejcts/ezad224.
7
Impact of FDG PET Standardized Uptake Value in Resected Clinical Stage IA Non-Small Cell Lung Cancer.切除的临床ⅠA 期非小细胞肺癌中 FDG PET 标准化摄取值的影响。
Ann Thorac Surg. 2024 May;117(5):1017-1023. doi: 10.1016/j.athoracsur.2023.04.013. Epub 2023 Apr 19.
8
Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer.肺段或亚肺叶切除术治疗外周型ⅠA 期非小细胞肺癌。
N Engl J Med. 2023 Feb 9;388(6):489-498. doi: 10.1056/NEJMoa2212083.
9
What is the appropriate "first lymph node" in the era of segmentectomy for non-small cell lung cancer?在非小细胞肺癌肺段切除术时代,合适的“第一站淋巴结”是什么?
Front Oncol. 2023 Jan 26;12:1078606. doi: 10.3389/fonc.2022.1078606. eCollection 2022.
10
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.帕博利珠单抗对比安慰剂作为完全切除的 IB 期-IIIA 期非小细胞肺癌的辅助治疗(PEARLS/KEYNOTE-091):一项随机、三盲、III 期试验的中期分析。
Lancet Oncol. 2022 Oct;23(10):1274-1286. doi: 10.1016/S1470-2045(22)00518-6. Epub 2022 Sep 12.